Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other financing activities (2018 - 2025)

Historic Other financing activities for Dexcom (DXCM) over the last 11 years, with Q4 2025 value amounting to -$1.9 million.

  • Dexcom's Other financing activities fell 1875.0% to -$1.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.0 million, marking a year-over-year increase of 4615.38%. This contributed to the annual value of -$7.0 million for FY2025, which is 4615.38% up from last year.
  • Dexcom's Other financing activities amounted to -$1.9 million in Q4 2025, which was down 1875.0% from -$1.7 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Other financing activities ranged from a high of $4.9 million in Q4 2023 and a low of -$8.7 million during Q1 2024
  • For the 5-year period, Dexcom's Other financing activities averaged around -$2.3 million, with its median value being -$1.5 million (2024).
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 385000.0% in 2021, then soared by 59000.0% in 2023.
  • Quarter analysis of 5 years shows Dexcom's Other financing activities stood at -$800000.0 in 2021, then dropped by 25.0% to -$1.0 million in 2022, then soared by 590.0% to $4.9 million in 2023, then tumbled by 132.65% to -$1.6 million in 2024, then decreased by 18.75% to -$1.9 million in 2025.
  • Its Other financing activities was -$1.9 million in Q4 2025, compared to -$1.7 million in Q3 2025 and -$1.7 million in Q2 2025.